Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CACNA2D1 | P54289 | 12/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313497 | 1.00 | F9 (0.50) | F9PLAUMEN1KMT2ACACNA2D1 | |
| SCHEMBL6274946 | 0.86 | KMT2A (0.50) | MEN1KMT2ACACNA2D1SMN1; SMN2HSD17B10 | |
| SCHEMBL3133596 | 0.86 | KMT2A (0.50) | MEN1KMT2ACACNA2D1SMN1; SMN2HSD17B10 | |
| SCHEMBL13318742 | 0.85 | CACNA2D1 (0.42) | MEN1KMT2ACACNA2D1FABP5NR3C1 | |
| SCHEMBL5756023 | 0.84 | KMT2A (0.49) | MEN1KMT2ACACNA2D1SMN1; SMN2HSD17B10 | |
| SCHEMBL5756012 | 0.84 | KMT2A (0.49) | MEN1KMT2ACACNA2D1SMN1; SMN2HSD17B10 | |
| SCHEMBL5756016 | 0.83 | MEN1 (0.43) | MEN1KMT2ACACNA2D1FABP5NR3C1 | |
| SCHEMBL15818865 | 0.79 | POLB (0.59) | MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL5792452 | 0.79 | POLB (0.59) | MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL5792686 | 0.79 | POLB (0.59) | MEN1KMT2ASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663234-A1 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTIONS | Pfizer Limited (GB) | 2006-06-07 | — | — | EP | disclosed |
| US-20050043300-A1 | Piperazine derivatives | PFIZER INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005016344-A1 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTIONS | PFIZER LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043300-A1 | Piperazine derivatives | CD4, CCR5, RRP15 | F9 3855/4885PLAU 4760/4885MEN1 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.